Moderna's Cancer Vaccine Shows Promise: Stock Doubles

Moderna's shares doubled following the release of promising results from its experimental cancer vaccine. The company's mRNA-based therapy is being used in combination with the existing cancer drug Keytruda. This combination has been reported to significantly reduce the risk of disease recurrence in patients with melanoma, a type of skin cancer. The disclosed data is seen as a strong signal of the treatment's efficacy and has attracted investor interest. Moderna notes that although its work in this area is at an early stage, the results have generated optimism about the commercial potential. Experts predict that such personalized cancer vaccines could become part of standard treatment protocols in the future. However, it is also emphasized that the data obtained at this stage are not yet conclusive and that broader clinical trials are needed. Investors view this development as a significant step in the company's long-term growth story. This is not investment advice.